Lineage Cell Therapeutics Investor Relations Material
Latest events
Q4 2023
Lineage Cell Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Lineage Cell Therapeutics Inc
Access all reports
Lineage Cell Therapeutics, Inc., a biotechnology company, develops cell therapies for the treatment of degenerative diseases. The company develops allogeneic cellular therapies from immortally differentiated human cells. It is developing VAC, an allogeneic cancer immunotherapy for the treatment of solid tumors; OPREGEN, an allogeneic retinal pigment epithelial cell product for the treatment of dry age-related macular degeneration, as well as wet age-related macular degeneration and diabetic eye diseases; Neo-Kidney Augment, an allogeneic product candidate that is in preclinical study to treat subjects with end stage renal disease.
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States